Peter Van Veldhuizen, MD
Combination immunotherapy approaches have emerged as a key strategy in the frontline paradigm for renal cell carcinoma (RCC). Not only have these combinations improved overall responses, but they have subtly “redefined frontline alternatives,” said Peter J. Van Veldhuizen, MD, a hematologist/oncologist at Sarah Cannon Research Institute.
on A Summer of Progress: Updates from ASCO 2018, Peter J. Van Veldhuizen, hematologist/oncologist, Sarah Cannon Research Institute, discussed available and emerging therapies for patients with kidney cancer.
OncLive: What are the most recent advances in the treatment of patients with kidney cancer?
: We looked at some key trials like the CABOSUN trial, which looked at first-line cabozantinib versus sunitinib for intermediate- and high-risk patients. CheckMate-214 compared frontline nivolumab and ipilimumab with sunitinib. Both of those trials showed improved survival in the study arm compared with sunitinib. These trials have somewhat redefined frontline alternatives.
In addition, we discussed the CARMENA trial, which looked at debulking nephrectomy in the metastatic setting in patients who received sunitinib alone versus debulking nephrectomy followed by sunitinib. [Debulking nephrectomy followed by sunitinib] did not show a survival advantage with sunitinib alone. There is still some question about the benefit [of nephrectomy] for selected patients.
What factors do you consider in deciding between the available frontline treatments?
The combination of nivolumab and ipilimumab is exciting because it resulted in some complete responses. The tolerability may be in question for certain patients. Performance status, age, and PD-1 status also play a role in whether or not you select that regimen.
... to read the full story